1. The Effect of Bevacizumab and Ranibizumab Injection
on Corneal Neovascularization
Doh Lee, M.D., Ph.D., Jin Hyoung Kim, M.D.,
Suk Kyue Choi, M.D., Se Hoon Park, M.D.
Department of Ophthalmology, Ilsan Paik Hospital,
Inje University College of Medicine, Gyeonggi, Korea
Authors have no financial interest

2. PURPOSE To evaluate the effect of regression and treatment
of subconjunctival and intralesional Bevacizumab (AvastinⓇ)
and Ranibizumab (LucentisⓇ) injection on corneal
neovascularization (CNV) resulting from different
ocular surface disorders
연구의 목적은 정상안과 라식후 수술안에서 서로 다른 4가지 각막두께측정계를 통해 중심각막두께를 비교해 보는 것입니다.

3. METHODS Group I - Bevacizumab - 1.25 mg/0.05cc injection only (n=5)
(AvastinⓇ; Genentech, Inc., San Francisco, CA)
mg/0.05cc injection only (n=5)
under topical anesthesia
Group II
- Ranibizumab
(LucentisⓇ ; Genentech, Inc., San Francisco, CA)
- 0.5 mg/0.05cc injection only (n=5)

4. Corneal herpes infection
METHODS
Charateristics of patients
Causes of NVs
Corneal herpes infection
Post-KP
Lipid degeneration
No. of eyes 6 2
Patients were followed up at 1, 7, 30 days after treatment.
Used Image J software (Wayne Rasband at the Research Services
Branch, National Institute of Mental Health, Bethesda, MD) to
analyze the vascularized corneal area.

5. Results - Area of CNV Bevacizumab 1.25mg/0.05cc injection (Group I)
< Post herpetic CNV with corneal opacity >
Pre injection
Post injection (POD # 7)
< Post KP CNV d/t Chemical burn >
Pre injection
Post injection (POD # 7)

6. Results - Area of CNV Bevacizumab 1.25mg/0.05cc injection (Group I)
< CNV d/t Lipid degeneration >
< CNV d/t corneal ulcer >
< Post Pterygium OP. >
Pre injection
Pre injection
Pre injection
Post injection (POD # 7)
Post injection (POD # 7)
Post injection (POD # 7)

7. (By using Image J software)
Results - Area of CNV
Bevacizumab 1.25mg/0.05cc injection (Group I)
(By using Image J software)

8. Results - Area of CNV Ranibizumab 0.5mg/0.05cc injection (Group II)
< Post KP CNV >
Pre injection
Post injection (POD # 7)
< CNV with corneal opacity d/t Lipid keratopathy >
Pre injection
Post injection (POD # 7)

9. Results - Area of CNV Ranibizumab 0.5mg/0.05cc injection (Group II)
< Post herpetic CNV with corneal opacity >
Pre injection
Post injection (POD # 7)
< Post herpetic CNV with corneal opacity >
Pre injection
Post injection (POD # 7)

10. (By using Image J software)
Results - Area of CNV
Ranibizumab 0.5mg/0.05cc injection (Group II)
중심각막두께의 결과입니다. 중심각막두께의 평균값은 그룹 1~4에서 GALILEI, Pentacam, US ,Orbscan II 순으로 각막두께가 측정되었습니다.
(By using Image J software)

11. Conclusions & Discussions
Subconjunctival and intralesional Bevacizumab
injection effectively regress CNV induced by various causes, whereas
there is no significant effect for CNS after Ranibizumab injection.
Bevacizumab injection were seems to be more effective to reduce CNV
than Ranibizumab injection.
Bevacizumab injection showed significant regression of CNV in short
period of time. After one month Bevacizumab injection, CNV had
tendency to recur and re-growth.

12. Conclusions & Discussions
Subconjunctival and intralesional Bevacizumab
injection could be considered a treatment option for
the CNVs.
Further research is needed to assess the potential
duration, side – effects and minimal effective dose.